Brief: Kymera Therapeutics Completes Enrollment In The Phase 2B Broaden2 Trial Of KT-621 In Atopic Dermatitis With Topline Data By Year-End 2026
25/06/2026 12:22
BRIEF-Kymera Therapeutics Completes Enrollment In The Phase 2B Broaden2 Trial Of KT-621 In Atopic Dermatitis With Topline Data By Year-End 2026 June 25 (Reuters) - Kymera Therapeutics Inc KYMR.O:
KYMERA THERAPEUTICS COMPLETES ENROLLMENT IN THE PHASE 2B BROADEN2 TRIAL OF KT-621 IN ATOPIC DERMATITIS WITH TOPLINE DATA BY YEAR-END 2026
KYMERA THERAPEUTICS COMPLETES ENROLLMENT IN THE PHASE 2B BROADEN2 TRIAL OF KT-621 IN ATOPIC DERMATITIS WITH TOPLINE DATA BY YEAR-END 2026
KYMERA THERAPEUTICS - TOPLINE DATA FOR BROADEN2 PHASE 2B TRIAL EXPECTED BY YEAR-END 2026
KYMERA THERAPEUTICS - PHASE 3 TRIALS IN ATOPIC DERMATITIS EXPECTED TO INITIATE BY MID-2027
KYMERA THERAPEUTICS - KT-621 BREADTH PHASE 2B ASTHMA TRIAL DATA EXPECTED IN LATE 2027
Source text: ID:nGNX3rD6JW
Further company coverage: KYMR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kymera Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Kymera Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates
Brief: Kymera Therapeutics Q2 EPS USD -0.62
Brief: Kymera Therapeutics Appoints Terence Rooney, MD, As Chief Medical Officer